Company Overview and News

9
AbbVie Has Issues, But It Isn't the 'Next Big Drug Short' - Bloomberg

31m bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
VRX ABBV ABBV

4
Ackman’s Comeback: How to Ride His Revival - Barron's

2018-07-17 barrons
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
GLRE TPRE ADP TPOG VRX PSHZF BAX UTX QSR.WI CMG ADPVV TPOU QSR

11
Is Trump Reining In Drug Prices? We're Keeping Track

2018-07-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ CNXR VRX ABBV 500680 PFE PFIZER ABBV

0
VRX / Valeant Pharmaceuticals International, Inc. FORM 8-K (Current Report)

2018-07-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION
VRX

2
Broadcom's 17% Price Drop Is A Gift

2018-07-16 seekingalpha
The acquisition will be significantly accretive and Broadcom has a long history of successful acquisitions and stock price increases.
VRX AVGO BRCM

4
Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

2018-07-16 zacks
Investors in Valeant Pharmaceuticals International, Inc. (VRX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 10, 2018 $16 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
VRX GTT VRX KRYS

0
Valeant starts trading as Bausch Health Cos. today, trading under ticker symbol 'BHC'

2018-07-16 marketwatch
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products.
VRX

0
Johnson and Johnson ordered to pay $742m in talc asbestos cancer case

2018-07-12 theage.com.au
Johnson & Johnson must pay at least $US550 million ($742 million) in damages to women who claimed asbestos in the company's talc products caused them to develop ovarian cancer, a St. Louis jury said.
NK VRX

0
Johnson and Johnson ordered to pay $742m in talc asbestos cancer case

2018-07-12 smh.com.au
Johnson & Johnson must pay at least $US550 million ($742 million) in damages to women who claimed asbestos in the company's talc products caused them to develop ovarian cancer, a St. Louis jury said.
NK VRX

0
J&J Ordered to Pay $550 Million in Talc Asbestos Cancer Case - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NK VRX

28
3 Real Risks That Could Make You Reconsider Buying Celgene Stock

2018-07-12 investorplace
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
VRX CELGZ GILD JUNO MCK CELG TEVA VRX NVS PFE

5
Broadcom Is Getting Desperate

2018-07-12 seekingalpha
Broadcom needs to keep making acquisitions in order to pro-forma out expenses and show non-GAAP EPS growth.
AVGO VRX CA QCOM

56
Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it.
BLU CYTX TEVA ISR TEVVF ZYNE NGS AVXL SNGX VRX INSP ACRS CYTXW BLUSF CELG CTYX OCX GLPG KMPH VRX GLPG CTIC CTI EGRX XLRN TEVJF PTCT

48
This Pick And Shovel Stock Is Still A Value

2018-07-10 seekingalpha
The real cash flows of corporate America are in decline, but certain sectors are still growing profits.
LRCX QQQ C AMZN AI GOOGL AMAT AAPL VRX TTM UCTT

85
XON / Intrexon Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-07 fintel.io
Intrexon Corp. (NYSE:XON) has 183 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,162,559 shares. Largest shareholders include Third Security, LLC, Iridian Asset Management Llc/ct, Vanguard Group Inc, FMR LLC / Fidelity, Lmm Llc, State Street Corp, First Trust Advisors Lp, Morgan Stanley, BlackRock Inc.
STT STT.PRC XON STT.PRE STT.PRD STT.PRG MS.PRE VRX MS.PRF MS.PRG ISRG MS.PRA PGNX BLK MS.PRI BSX MS.PRK ICUI MS SLXP MZOR

VRX: Valeant Pharmaceuticals International Stock Analysis and Research Report

2017-09-28 - Asif

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products. The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to VRX / Valeant Pharmaceuticals International, Inc. on message board site Silicon Investor.

Valeant Pharmaceuticals (VRX) Valeant Pharmaceuticals (VRX)
Avalon Pharmaceuticals (AVRX)
CUSIP: 91911K102